Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This edition of Medical Crossfire® provides community oncologists with evidence-based perspectives on the rationale for current standards of care in soft tissue sarcoma (STS), clinical questions and challenges, and how to integrate optimal approaches into clinical practice. It is designed to update practitioners on advances in the field and focuses on the appropriate diagnosis of STS, multi-disciplinary management, use of new agents, and the value of appropriate referral to a sarcoma specialist under a collaborative-care model. Our program chair, George Demetri, MD, leads the program faculty, Mark Agulnik, MD, Shreyaskumar R. Patel, MD, and Richard F. Riedel in extensive panel discussions on 3 key topics. Throughout the activity, interactive online questions are posted to participants to assess their knowledge and facilitate self-assessment.
Requirements for Successful Completion
Participants may immediately download a CME certificate upon completion of these steps.
This educational program is directed toward medical oncologists, surgical oncologists, and radiation oncologists in the treatment of soft tissue sarcoma. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with sarcoma will be invited to participate.
George D. Demetri, MD
Professor of Medicine, Harvard Medical School
Director, Ludwig Center at Harvard
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
Disclosure: Grant/Research Support: Bayer, Novartis, Pfizer, Janssen Oncology; Consultant: Novartis, Pfizer, EMD Serono, Sanofi Oncology, Janssen Oncology, PharmaMar, Daiichi-Sankyo, Adaptimmune, Eisai, Blueprint Medicines, Kolltan Pharmaceuticals, Caris Life Sciences.
FacultyMark Agulnik, MD
Richard F. Riedel, MD
This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
ONS: PER Forum™: Nursing Opportunities to Improve Outcomes With the Advent of PARP Inhibitors in the Care of Women’s Cancers
May 17, 2018
ONS: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for Nurses
May 17, 2018
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of Cancers
May 30, 2018
May 31, 2018
May 31, 2018